Fei Yu-Tong, Liu Jian-Ping
Evidence Based Medicine Centre, Beijing University of Chinese Medicine, Beijing 100029, China.
Zhongguo Zhong Yao Za Zhi. 2008 Jan;33(1):89-94.
Based on detailed explanation of the herbal CONSORT statement, and the consideration of the character of traditional Chinese drugs, to discuss the standardization of reporting traditional Chinese drug trials. The standards of reporting traditional Chinese drug trials are not consolidated yet. In the year 2006, Reporting Randomized, Controlled Trials of Herbal Interventions: An Elaborated CONSORT Statement was developed by the CONSORT group and published. This herbal CONSORT statement includes 5 parts, and totally 22 items, in which the items of participant criteria, intervention, control setting and outcomes, et al. are elaborated to be adaptable to herbal intervention trials. This herbal CONSORT statement has provided valuable basis for the development of standards of reporting traditional Chinese drug trials, though it is not completely adaptive to be the reporting standards in consideration of the background theory and the animal drugs and mineral drugs that traditional Chinese drugs contain. The proper reporting standards of traditional Chinese drug trials should take the different types of drugs and the different purposes of trials into consideration. The trial reports of drugs that must be applied under the instruction of traditional Chinese medicine (TCM) theory should report participant criteria that include TCM syndrome differentiation and other important characters of TCM interventions.
基于对草药CONSORT声明的详细阐释,并考虑到中药的特性,探讨中药试验报告的规范化问题。目前中药试验报告的标准尚未统一。2006年,CONSORT小组制定并发表了《草药干预随机对照试验报告:CONSORT详细声明》。该草药CONSORT声明包括5部分,共22项内容,其中对受试者标准、干预措施、对照设置和结局等项目进行了详细阐述,以适应草药干预试验。尽管考虑到中药所包含的背景理论以及动物药和矿物药等因素,该草药CONSORT声明并不完全适用于作为报告标准,但它为中药试验报告标准的制定提供了有价值的依据。中药试验恰当的报告标准应考虑不同类型的药物和不同的试验目的。必须在中医理论指导下应用的药物试验报告,应报告包括中医辨证及其他中医干预重要特征的受试者标准。